{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T17:26:59Z","timestamp":1786901219993,"version":"build-2736575974"},"publisher-location":"New York, NY","reference-count":86,"publisher":"Springer US","isbn-type":[{"value":"9781071654194","type":"print"},{"value":"9781071654200","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5420-0_6","type":"book-chapter","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T15:44:28Z","timestamp":1786895068000},"page":"91-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Small Molecules: Applying Fragment Molecular Orbital Sygnature Platform (FMO-SP) to Emerging Modalities"],"prefix":"10.1007","author":[{"given":"Alexander","family":"Heifetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girinath G.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryamdokht","family":"Taimoory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin Sambrook","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1021\/acsmedchemlett.2c00375","volume":"13","author":"M-J Blanco","year":"2022","unstructured":"Blanco M-J, Gardinier KM, Namchuk MN (2022) Advancing new chemical modalities into clinical studies. ACS Med Chem Lett 13:1691\u20131698","journal-title":"ACS Med Chem Lett"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1021\/acsmedchemlett.9b00582","volume":"11","author":"M-J Blanco","year":"2020","unstructured":"Blanco M-J, Gardinier KM (2020) New chemical modalities and strategic thinking in early drug discovery. ACS Med Chem Lett 11:228\u2013231","journal-title":"ACS Med Chem Lett"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1021\/acsmedchemlett.1c00476","volume":"12","author":"CE M\u00fcller","year":"2021","unstructured":"M\u00fcller CE, Hansen FK, G\u00fctschow M et al (2021) New drug modalities in medicinal chemistry, pharmacology, and translational science: joint virtual special issue by Journal of\u00a0Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science. ACS Med Chem Lett 12:1508\u20131509","journal-title":"ACS Med Chem Lett"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"10294","DOI":"10.1002\/anie.201611914","volume":"56","author":"E Valeur","year":"2017","unstructured":"Valeur E, Gu\u00e9ret SM, Adihou H et al (2017) New modalities for challenging targets in drug discovery. Angew Chem Int Ed 56:10294\u201310323","journal-title":"Angew Chem Int Ed"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5599\/admet.1209","volume":"9","author":"M Kansy","year":"2021","unstructured":"Kansy M, Caron G (2021) New therapeutic modalities in drug discovery and development: insights & opportunities. ADMET DMPK 9:227\u2013230","journal-title":"ADMET DMPK"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cpt.2996","volume":"114","author":"Y Choi","year":"2023","unstructured":"Choi Y, Vinks AA, Van Der Graaf PH (2023) Novel therapeutic modalities: the future is now. Clin Pharmacol Ther 114:493\u2013496","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.apsb.2022.03.009","volume":"12","author":"Y Lai","year":"2022","unstructured":"Lai Y, Chu X, Di L et al (2022) Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharm Sin B 12:2751\u20132777","journal-title":"Acta Pharm Sin B"},{"key":"6_CR8","doi-asserted-by":"crossref","unstructured":"De La Torre BG, Albericio F (2025) The pharmaceutical industry in 2024: an analysis of FDA drug approvals from the perspective of\u2002molecules.\u2002https:\/\/www.preprints.org\/manuscript\/202501.0253\/v1","DOI":"10.20944\/preprints202501.0253.v1"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00210-024-03063-1","volume":"397","author":"G Kayki-Mutlu","year":"2024","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L et al (2024) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023. Naunyn Schmiedebergs Arch Pharmacol 397:2949\u20132970","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"1486812","DOI":"10.3389\/fphar.2024.1486812","volume":"15","author":"J Yoon","year":"2025","unstructured":"Yoon J, Lee S, Kim MJ et al (2025) Brief summary of the regulatory frameworks of regenerative medicine therapies. Front Pharmacol 15:1486812","journal-title":"Front Pharmacol"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/biomedicines12091992","volume":"12","author":"AC Martins","year":"2024","unstructured":"Martins AC, Oshiro MY, Albericio F et al (2024) Food and Drug Administration (FDA) approvals of biological drugs in 2023. Biomedicines 12:1992","journal-title":"Biomedicines"},{"key":"6_CR12","first-page":"197","volume":"8","author":"WR Strohl","year":"2025","unstructured":"Strohl WR (2025) Structure and function of therapeutic antibodies approved by the US FDA in 2024. Antib Ther 8:197\u2013237","journal-title":"Antib Ther"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biom14010099","volume":"14","author":"J Lee","year":"2024","unstructured":"Lee J, Beers JL, Geffert RM et al (2024) A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment. Biomolecules 14:99","journal-title":"Biomolecules"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","volume":"24","author":"LLG Ferreira","year":"2019","unstructured":"Ferreira LLG, Andricopulo AD (2019) ADMET modeling approaches in drug discovery. Drug Discov Today 24:1157\u20131165","journal-title":"Drug Discov Today"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","volume":"20","author":"MJ Henley","year":"2021","unstructured":"Henley MJ, Koehler AN (2021) Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules. Nat Rev Drug Discov 20:669\u2013688","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-025-02214-x","volume":"23","author":"C Qin","year":"2025","unstructured":"Qin C, Wang Y-L, Zheng J et al (2025) Current perspectives in drug targeting intrinsically disordered proteins and biomolecular condensates. BMC Biol 23: 118","journal-title":"BMC Biol"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21445","volume":"38","author":"S Kalyaanamoorthy","year":"2018","unstructured":"Kalyaanamoorthy S, Barakat KH (2018) Development of safe drugs: the hERG challenge. Med Res Rev 38:525\u2013555","journal-title":"Med Res Rev"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"eaaw8412","DOI":"10.1126\/scitranslmed.aaw8412","volume":"11","author":"A Lin","year":"2019","unstructured":"Lin A, Giuliano CJ, Palladino A et al (2019) Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 11:eaaw8412","journal-title":"Sci Transl Med"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"13121","DOI":"10.3390\/ijms252313121","volume":"25","author":"K Wu","year":"2024","unstructured":"Wu K, Kwon SH, Zhou X et al (2024) Overcoming challenges in small-molecule drug bioavailability: a review of key factors and approaches. Int J Mol Sci 25:13121","journal-title":"Int J Mol Sci"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie X, Yu T, Li X et al (2023) Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Transduct Target Ther 8:335","journal-title":"Signal Transduct Target Ther"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6:201","journal-title":"Signal Transduct Target Ther"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood\u2013brain barrier: bottleneck in brain drug development. NeuroRx 2:3\u201314","journal-title":"NeuroRx"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X et al (2023) The blood\u2013brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther 8:217","journal-title":"Signal Transduct Target Ther"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","volume":"4","author":"Z Lei","year":"2023","unstructured":"Lei Z, Tian Q, Teng Q et al (2023) Understanding and targeting resistance mechanisms in cancer. MedComm 4:e265","journal-title":"MedComm"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H et al (2022) Why 90% of clinical drug development fails and how to improve it?. Acta Pharm Sin B 12:3049\u20133062","journal-title":"Acta Pharm Sin B"},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R-M Lu","year":"2020","unstructured":"Lu R-M, Hwang Y-C, Liu I-J et al (2020) Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 27:1","journal-title":"J Biomed Sci"},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","volume":"17","author":"HM Shepard","year":"2017","unstructured":"Shepard HM, Phillips GL, Thanos CD et al (2017) Developments in therapy with monoclonal antibodies and related proteins. Clin Med 17:220\u2013232","journal-title":"Clin Med"},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"780106","DOI":"10.3389\/fmolb.2021.780106","volume":"8","author":"L Belvisi","year":"2021","unstructured":"Belvisi L, D\u2019Andrea LD, Jim\u00e9nez MA (2021) Editorial: peptides targeting protein-protein interactions: methods and applications. Front Mol Biosci 8:780106","journal-title":"Front Mol Biosci"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"682675","DOI":"10.3389\/fchem.2021.682675","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang X, Ni D, Liu Y et al (2021) Rational design of peptide-based inhibitors disrupting protein-protein interactions. Front Chem 9:682675","journal-title":"Front Chem"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"107544","DOI":"10.1016\/j.phrs.2024.107544","volume":"211","author":"C Camps-Fajol","year":"2025","unstructured":"Camps-Fajol C, Cavero D, Minguill\u00f3n J et al (2025) Targeting protein-protein interactions in drug discovery: modulators approved or in clinical trials for cancer treatment. Pharmacol Res 211:107544","journal-title":"Pharmacol Res"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrd.2016.29","volume":"15","author":"DE Scott","year":"2016","unstructured":"Scott DE, Bayly AR, Abell C et al (2016) Small molecules, big targets: drug discovery faces the protein\u2013protein interaction challenge. Nat Rev Drug Discov 15:533\u2013550","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang L, Wang N, Zhang W et al (2022) Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 7:48","journal-title":"Signal Transduct Target Ther"},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1126\/science.274.5289.948","volume":"274","author":"PH Kussie","year":"1996","unstructured":"Kussie PH, Gorina S, Marechal V et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948\u2013953","journal-title":"Science"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202\u2013208","journal-title":"Nat Med"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak KM, Kitel R, Przetocka S et al (2015) Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23:2341\u20132348","journal-title":"Structure"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"110712","DOI":"10.1016\/j.isci.2024.110712","volume":"27","author":"X Tan","year":"2024","unstructured":"Tan X, Huang Z, Pei H et al (2024) Molecular glue-mediated targeted protein degradation: a novel strategy in small-molecule drug development. iScience 27:110712","journal-title":"iScience"},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","volume":"31","author":"M Konstantinidou","year":"2024","unstructured":"Konstantinidou M, Arkin MR (2024) Molecular glues for protein-protein interactions: progressing toward a new dream. Cell Chem Biol 31:1064\u20131088","journal-title":"Cell Chem Biol"},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","volume":"64","author":"G Dong","year":"2021","unstructured":"Dong G, Ding Y, He S et al (2021) Molecular glues for targeted protein degradation: from serendipity to rational discovery. J Med Chem 64:10606\u201310620","journal-title":"J Med Chem"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","volume":"62","author":"JM Sasso","year":"2023","unstructured":"Sasso JM, Tenchov R, Wang D et al (2023) Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry 62:601\u2013623","journal-title":"Biochemistry"},{"key":"6_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1039\/D2CB00207H","volume":"4","author":"H Rui","year":"2023","unstructured":"Rui H, Ashton KS, Min J et al (2023) Protein\u2013protein interfaces in molecular glue-induced ternary complexes: classification, characterization, and prediction. RSC Chem Biol 4:192\u2013215","journal-title":"RSC Chem Biol"},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K et al (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 7:113","journal-title":"Signal Transduct Target Ther"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s00044-022-02882-2","volume":"31","author":"EG Weagel","year":"2022","unstructured":"Weagel EG, Foulks JM, Siddiqui A et al (2022) Molecular glues: enhanced protein\u2013protein interactions and cell proteome editing. Med Chem Res 31:1068\u20131087","journal-title":"Med Chem Res"},{"key":"6_CR43","first-page":"680","volume":"31","author":"I Abraham","year":"2025","unstructured":"Abraham I, Martin P, Vaghela S et al (2025) Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with a KMT2A translocation in the United States. J Manag Care Spec Pharm 31:680\u2013693","journal-title":"J Manag Care Spec Pharm"},{"key":"6_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","volume":"3","author":"Z Liu","year":"2022","unstructured":"Liu Z, Hu M, Yang Y et al (2022) An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed 3:46","journal-title":"Mol Biomed"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","volume":"14","author":"F Riccardi","year":"2023","unstructured":"Riccardi F, Dal Bo M, Macor P et al (2023) A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol 14:1274088","journal-title":"Front Pharmacol"},{"key":"6_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C et al (2017) Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov 16:315\u2013337","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR47","doi-asserted-by":"crossref","unstructured":"Jadhav K, Abhang A, Kole EB et al (2025) Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress. https:\/\/www.preprints.org\/manuscript\/202503.1521\/v1","DOI":"10.20944\/preprints202503.1521.v1"},{"key":"6_CR48","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M (2023) Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 51:2529\u20132573","journal-title":"Nucleic Acids Res"},{"key":"6_CR49","doi-asserted-by":"publisher","first-page":"e70342","DOI":"10.1002\/mco2.70342","volume":"6","author":"Z Cai","year":"2025","unstructured":"Cai Z, Ma H, Ye F et al (2025) Discovery of RNA-targeting small molecules: challenges and future directions. MedComm 6:e70342","journal-title":"MedComm"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"102440","DOI":"10.1016\/j.omtn.2024.102440","volume":"36","author":"S Naeem","year":"2025","unstructured":"Naeem S, Zhang J, Zhang Y et al (2025) Nucleic acid therapeutics: past, present, and future. Mol Ther Nucleic Acids 36:102440","journal-title":"Mol Ther Nucleic Acids"},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"6_CR52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","volume":"17","author":"CA Chiriboga","year":"2017","unstructured":"Chiriboga CA (2017) Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother 17:955\u2013962","journal-title":"Expert Rev Neurother"},{"key":"6_CR53","first-page":"103545","volume":"73","author":"F Zahedipour","year":"2025","unstructured":"Zahedipour F, Gol TM, Wisser S et al (2025) Revolutionizing pediatric gene and cell therapy: the hope for lipid-based nanoparticles in blood disorders. Curr Res Transl Med 73:103545","journal-title":"Curr Res Transl Med"},{"key":"6_CR54","doi-asserted-by":"crossref","unstructured":"Li B, Chen Y, Zhang Y et al (2025) Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS). Expert Opin Drug Saf 25(4):657\u2013668","DOI":"10.1080\/14740338.2025.2468855"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/vaccines13080855","volume":"13","author":"J Szebeni","year":"2025","unstructured":"Szebeni J, Koller A (2025) Multisystem endothelial inflammation: a key driver of adverse events following mRNA-containing COVID-19 vaccines. Vaccines 13:855","journal-title":"Vaccines"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"103536","DOI":"10.1016\/j.eclinm.2025.103536","volume":"88","author":"O Keritam","year":"2025","unstructured":"Keritam O, Erdler M, Fasching B et al (2025) Efficacy and safety of risdiplam in adults with 5q-associated spinal muscular atrophy: a nationwide observational cohort study in Austria. eClinicalMedicine 88:103536","journal-title":"eClinicalMedicine"},{"key":"6_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12982-024-00229-3","volume":"21","author":"RBO Ouma","year":"2024","unstructured":"Ouma RBO, Ngari SM, Kibet JK (2024) A review of the current trends in computational approaches in drug design and metabolism. Discov Public Health 21:108","journal-title":"Discov Public Health"},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351","journal-title":"Mol Metab"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3803\/EnM.2024.1940","volume":"39","author":"JW Son","year":"2024","unstructured":"Son JW, Lim S (2024) Glucagon-like peptide-1 based therapies: a new horizon in obesity management. Endocrinol Metab 39:206\u2013221","journal-title":"Endocrinol Metab"},{"key":"6_CR60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9:234","journal-title":"Signal Transduct Target Ther"},{"key":"6_CR61","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1021\/acs.jmedchem.6b00045","volume":"59","author":"A Heifetz","year":"2016","unstructured":"Heifetz A, Trani G, Aldeghi M et al (2016) Fragment molecular orbital method applied to lead optimization of novel interleukin-2 inducible T-cell kinase (ITK) inhibitors. J Med Chem 59:4352\u20134363","journal-title":"J Med Chem"},{"key":"6_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-0716-0282-9_3","volume-title":"Quantum mechanics in drug discovery","author":"A Heifetz","year":"2020","unstructured":"Heifetz A, James T, Southey M et al (2020) Guiding medicinal chemistry with fragment molecular orbital (FMO) Method. In: Heifetz A (Ed.)Eds. Quantum mechanics in drug discovery. Springer US, New York, NY, 37\u201348"},{"key":"6_CR63","doi-asserted-by":"publisher","first-page":"106152","DOI":"10.1016\/j.jsbmb.2022.106152","volume":"222","author":"C Handa","year":"2022","unstructured":"Handa C, Yamazaki Y, Yonekubo S et al (2022) Evaluating the correlation of binding affinities between isothermal titration calorimetry and fragment molecular orbital method of estrogen receptor beta with diarylpropionitrile (DPN) or DPN derivatives. J Steroid Biochem Mol Biol 222:106152","journal-title":"J Steroid Biochem Mol Biol"},{"key":"6_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.sbi.2021.08.010","volume":"72","author":"K Fukuzawa","year":"2022","unstructured":"Fukuzawa K, Tanaka S (2022) Fragment molecular orbital calculations for biomolecules. Curr Opin Struct Biol 72:127\u2013134","journal-title":"Curr Opin Struct Biol"},{"key":"6_CR65","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.1039\/c2cp23784a","volume":"14","author":"DG Fedorov","year":"2012","unstructured":"Fedorov DG, Nagata T, Kitaura K (2012) Exploring chemistry with the fragment molecular orbital method. Phys Chem Chem Phys 14:7562","journal-title":"Phys Chem Chem Phys"},{"key":"6_CR66","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jcc.20496","volume":"28","author":"DG Fedorov","year":"2007","unstructured":"Fedorov DG, Kitaura K (2007) Pair interaction energy decomposition analysis. J Comput Chem 28:222\u2013237","journal-title":"J Comput Chem"},{"key":"6_CR67","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1110\/ps.26002","volume":"11","author":"A Heifetz","year":"2002","unstructured":"Heifetz A, Katchalski-Katzir E, Eisenstein M (2002) Electrostatics in protein\u2013protein docking. Protein Sci 11:571\u2013587","journal-title":"Protein Sci"},{"key":"6_CR68","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1089\/adt.2010.0322","volume":"8","author":"AJ Davenport","year":"2010","unstructured":"Davenport AJ, M\u00f6ller C, Heifetz A et al (2010) Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-\u00e0-go-go related gene K+ channel inhibition in a histamine H3 receptor antagonist program. Assay Drug Dev Technol 8:781\u2013789","journal-title":"Assay Drug Dev Technol"},{"key":"6_CR69","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1021\/acs.jpca.6b00163","volume":"120","author":"DG Fedorov","year":"2016","unstructured":"Fedorov DG, Kitaura K (2016) Subsystem analysis for the fragment molecular orbital method and its application to protein\u2013ligand binding in solution. J Phys Chem A 120:2218\u20132231","journal-title":"J Phys Chem A"},{"key":"6_CR70","doi-asserted-by":"publisher","first-page":"e202400170","DOI":"10.1002\/cphc.202400170","volume":"25","author":"DG Fedorov","year":"2024","unstructured":"Fedorov DG (2024) The peptide bond: resonance increases bond order and complicates fragmentation. ChemPhysChem 25:e202400170","journal-title":"ChemPhysChem"},{"key":"6_CR71","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1021\/acs.jcim.2c00457","volume":"62","author":"S Monteleone","year":"2022","unstructured":"Monteleone S, Fedorov DG, Townsend-Nicholson A et al (2022) Hotspot identification and drug design of protein\u2013protein interaction modulators using the fragment molecular orbital method. J Chem Inf Model 62:3784\u20133799","journal-title":"J Chem Inf Model"},{"key":"6_CR72","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser AS, Attwood MM, Rask-Andersen M et al (2017) Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16:829\u2013842","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/ars.2017.7168","volume":"29","author":"C Recio","year":"2018","unstructured":"Recio C, Lucy D, Iveson P et al (2018) The role of metabolite-sensing G protein-coupled receptors in inflammation and metabolic disease. Antioxid Redox Signal 29:237\u2013256","journal-title":"Antioxid Redox Signal"},{"key":"6_CR74","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","volume":"181","author":"M Congreve","year":"2020","unstructured":"Congreve M, De Graaf C, Swain NA et al (2020) Impact of GPCR structures on drug discovery. Cell 181:81\u201391","journal-title":"Cell"},{"key":"6_CR75","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002","journal-title":"N Engl J Med"},{"key":"6_CR76","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841\u2013851","journal-title":"N Engl J Med"},{"key":"6_CR77","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"6_CR78","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/dom.14638","volume":"24","author":"F Gomez-Peralta","year":"2022","unstructured":"Gomez-Peralta F, Choudhary P, Cosson E et al (2022) Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes Obes Metab 24:599\u2013608","journal-title":"Diabetes Obes Metab"},{"key":"6_CR79","doi-asserted-by":"publisher","first-page":"109374","DOI":"10.1016\/j.celrep.2021.109374","volume":"36","author":"X Zhang","year":"2021","unstructured":"Zhang X, Belousoff MJ, Liang Y-L et al (2021) Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep 36:109374","journal-title":"Cell Rep"},{"key":"6_CR80","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","volume":"65","author":"DA Griffith","year":"2022","unstructured":"Griffith DA, Edmonds DJ, Fortin J-P et al (2022) A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. J Med Chem 65:8208\u20138226","journal-title":"J Med Chem"},{"key":"6_CR81","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T et al (2016) A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535:252\u2013257","journal-title":"Nature"},{"key":"6_CR82","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acsmedchemlett.4c00534","volume":"16","author":"S Monteleone","year":"2025","unstructured":"Monteleone S, Morao I, Fedorov DG et al (2025) Quantum mechanics-based ranking of predicted proteolysis targeting chimeras-mediated ternary complexes. ACS Med Chem Lett 16:420\u2013427","journal-title":"ACS Med Chem Lett"},{"key":"6_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39904-5","volume":"14","author":"RP Wurz","year":"2023","unstructured":"Wurz RP, Rui H, Dellamaggiore K et al (2023) Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun 14: 4177","journal-title":"Nat Commun"},{"key":"6_CR84","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acschembio.9b00092","volume":"14","author":"MJ Roy","year":"2019","unstructured":"Roy MJ, Winkler S, Hughes SJ et al (2019) SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate. ACS Chem Biol 14:361\u2013368","journal-title":"ACS Chem Biol"},{"key":"6_CR85","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.csbj.2023.02.042","volume":"21","author":"TM Tunjic","year":"2023","unstructured":"Tunjic TM, Weber N, Brunsteiner M (2023) Computer aided drug design in the development of proteolysis targeting chimeras. Comput Struct Biotechnol J 21:2058\u20132067","journal-title":"Comput Struct Biotechnol J"},{"key":"6_CR86","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd MS, Testa A, Lucas X et al (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13:514\u2013521","journal-title":"Nat Chem Biol"}],"container-title":["Methods in Molecular Biology","Quantum Mechanics Applications in Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5420-0_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T17:01:21Z","timestamp":1786899681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5420-0_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654194","9781071654200"],"references-count":86,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5420-0_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"17 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}